https://www.onclive.com/view/glofitamab-in-relapsed-refractory-dlbcl-fixed-duration-therapy-and-crs-timing
Glofitamab in Relapsed/Refractory DLBCL: Fixed-Duration Therapy and CRS Timing | OncLive
Oct 6, 2026 - Dr. Chavez reviews glofitamab, the second bispecific antibody approved for relapsed/refractory DLBCL, and compares its pivotal data with those of epcoritamab.
glofitamabrelapsedrefractorydlbclfixed
https://database.inahta.org/article/33604
[Glofitamab (DLBCL, combinatio
glofitamabdlbclcombinatio